Publications

Scientific Presentations & Publications

Stay in the know about our company, science and our aspiration to use gene therapy to restore vision and prevent blindness.

View All

FLORetina 2025

Presentations December 4, 2025

ARVO 2025

Presentations May 9, 2025

AAO 2024

Presentations October 17, 2024

Retina Society 2024

Presentations September 13, 2024

ASRS 2024

Presentations July 17, 2024

Publications

Sort by Date:

FLORetina 2025

Ixo-vec Gene Therapy for nAMD: Clinical Progress from the LUNA Phase 2 Trial

Presentations| December 4, 2025

ARVO 2025

In Situ Hybridization Demonstrates Ocular Distribution of Ixo-vec IVT Gene Therapy in Human Cadaver Eye with wAMD and Supports Durable Clinical Efficacy

Presentations| May 9, 2025

AAO 2024

Addressing Unmet Needs for Patients with Wet AMD

Presentations| October 17, 2024

Retina Society 2024

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: 26-Week Interim Analysis Results from the Phase 2 LUNA Study

Presentations| September 13, 2024

ASRS 2024

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study

Presentations| July 17, 2024

Macula Society 2024

Ixoberogene soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration: Preliminary Results from the Phase 2 LUNA Study

Presentations| February 8, 2024

eClinicalMedicine – The Lancet

Safety and Efficacy of Ixoberogene Soroparvovec in Neovascular Age-Related Macular Degeneration in the United States (OPTIC): a Prospective, Two-Year, Multicentre Phase 1 Study

Publications| December 22, 2023

AAO 2023

Ixo-vec Intravitreal Gene Therapy for Neovascular AMD: 3-Year Results from the Phase 1 OPTIC Extension Trial and Preliminary Data from the Phase 2 LUNA Trial

Presentations| November 4, 2023

ESGCT 2023

Dose-dependent Inflammation Signatures Following Ixo-vec Administration in Non-human Primates

Presentations| October 25, 2023

ESGCT 2023

Functional and Molecular Evaluation of Intravitreal (IVT) AAV Gene Therapy Vectors for the Treatment of Geographic Atrophy (GA)

Presentations| October 25, 2023

ASGCT 2023

Intravitreal Delivery of Ixo-vec for Neovascular Age-Related Macular Degeneration Results in Widespread Expression of Aflibercept in Cynomolgus Monkey Eyes as Confirmed Using In-Situ Hybridization

Presentations| May 19, 2023

ASGCT 2023

Development of an Intravitreal (IVT) Gene Therapy for Geographic Atrophy (GA) by Overexpressing Complement Factor I (CFI) to Inhibit the Complement Cascade

Presentations| May 18, 2023